
RXDX
Healthcare · Biotechnology & Medical Research · $9.56B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2023 | Time not confirmed | -0.98 | 0.00 | +100.0% |
| Aug 10, 2023 | Time not confirmed | -0.94 | 0.00 | +100.0% |
| May 9, 2023 | After the close | -0.91 | -0.86 | +5.5% |
| Feb 28, 2023 | After the close | -0.92 | -0.90 | +2.2% |
| Nov 9, 2022 | After the close | -0.90 | -0.90 | 0.0% |
| Aug 11, 2022 | After the close | -0.91 | -0.86 | +5.5% |
| May 12, 2022 | After the close | -0.79 | -0.82 | -3.8% |
| Mar 9, 2022 | After the close | -0.68 | -0.77 | -13.2% |
| Nov 12, 2021 | Before the open | -0.59 | -0.70 | -18.6% |
| Aug 11, 2021 | After the close | -0.39 | -0.49 | -25.6% |
| May 13, 2021 | After the close | -0.37 | -1.67 | -351.4% |
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic…